Key Events This Week
23 Mar: Stock declines 1.41% amid broad market sell-off
24 Mar: Hits upper circuit at Rs.30.29, surging 4.16%
25 Mar: Recovers modestly, closing flat at Rs.29.36 (+1.14%)
27 Mar: Plunges to lower circuit, closing at Rs.28.41 (-3.24%)
23 March 2026: Market Sell-Off Weighs on Stock
Mangalam Drugs opened the week on a weak note, closing at Rs.29.36, down 1.41% from the previous close of Rs.29.78. This decline occurred amid a sharp Sensex drop of 3.13%, reflecting broad market weakness. The stock’s volume was modest at 2,279 shares, indicating limited trading interest. The decline aligned with the overall negative sentiment in the Pharmaceuticals & Biotechnology sector and the wider market, setting a cautious tone for the week ahead.
24 March 2026: Upper Circuit Triggered on Strong Buying Interest
In a striking reversal, Mangalam Drugs surged 4.16% to hit its upper circuit limit at Rs.30.29. The stock traded within a range of Rs.29.02 to Rs.30.53, with the upper circuit triggered at the maximum permissible 5% price increase for the day. This rally was driven by intense buying pressure despite the stock’s recent underperformance relative to its sector and the Sensex, which gained 1.95% on the day.
Trading volume increased significantly to 14,565 shares, though delivery volumes declined by 48.11% compared to the five-day average, suggesting speculative or intraday trading rather than sustained accumulation. The regulatory freeze on fresh buy orders was activated due to the circuit hit, indicating excess demand and unfilled buy orders. Despite this short-term strength, the stock remained below all key moving averages, signalling an ongoing downtrend.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
25 March 2026: Modest Recovery Amid Sector Gains
The stock rebounded slightly, closing at Rs.29.36, up 1.14% from the previous day’s close. This modest gain came alongside a 1.93% rise in the Sensex and reflected a partial retracement of the prior day’s volatility. Volume remained moderate at 2,743 shares, while delivery volumes continued to lag, down 48.39% from the five-day average. The Pharmaceuticals & Biotechnology sector also posted gains, though the stock’s performance remained cautious given its technical positioning below key averages.
27 March 2026: Lower Circuit Hit Amid Heavy Selling Pressure
After no trading data on 26 March, Mangalam Drugs plunged sharply on 27 March, hitting the lower circuit limit and closing at Rs.28.41, down 3.24% on the day and 4.60% for the week. The stock opened near Rs.30.50 but succumbed to intense selling, hitting a low of Rs.28.43 before settling near the circuit floor. This decline was more severe than the Pharmaceuticals & Biotechnology sector’s 0.41% fall and the Sensex’s 2.11% drop, underscoring company-specific weakness.
Trading volume surged to 8,087 shares, with a turnover of approximately ₹0.0747 crore. The lower circuit hit reflected panic selling and an imbalance between supply and demand, with sellers aggressively offloading shares and buyers scarce. Technical indicators remain bearish, with the stock trading below all major moving averages and declining delivery volumes signalling weak investor participation.
Holding Mangalam Drugs and Organics Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-23 | Rs.29.36 | -1.41% | 32,377.87 | -3.13% |
| 2026-03-24 | Rs.30.29 | +4.16% | 33,009.57 | +1.95% |
| 2026-03-25 | Rs.29.36 | +1.14% | 33,645.89 | +1.93% |
| 2026-03-27 | Rs.28.41 | -3.24% | 32,935.19 | -2.11% |
Key Takeaways
Volatility and Circuit Hits: The week was dominated by extreme price volatility, with Mangalam Drugs hitting both upper and lower circuit limits. The upper circuit on 24 March was driven by speculative buying and unfilled demand, while the lower circuit on 27 March reflected panic selling and weak investor confidence.
Underperformance vs Market and Sector: Despite a brief rally, the stock underperformed the Sensex and its sector over the week, closing down 4.60% compared to the Sensex’s 1.46% decline. This divergence highlights company-specific challenges amid broader market fluctuations.
Technical Weakness: The stock remains below all major moving averages, signalling a sustained downtrend. Declining delivery volumes further indicate weak genuine investor participation, raising concerns about the durability of any rallies.
Liquidity Constraints: As a micro-cap stock with a market capitalisation near ₹47 crore, Mangalam Drugs is susceptible to sharp price swings on relatively low volumes, contributing to its heightened volatility and circuit breaker events.
Fundamental Concerns: The company holds a Mojo Score of 3.0 with a Strong Sell grade, reflecting ongoing fundamental weaknesses and operational challenges that continue to weigh on investor sentiment.
Investors should remain cautious given the stock’s technical and fundamental profile, monitoring upcoming developments and sector trends closely before considering exposure.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
